EUVIMEDEUVIMED entdecken
Crossref

Efficient LAMA1 Gene Activation by Epigenome Editing as a Therapeutic Approach for LAMA2-CMD

Yuanbo Qin, Talha Akbulut, Rajakumar Mandraju, Keith Connolly, John Bechill, Farzaneh Assadian, Claudia Foster, Alison Shottek, Seth Levy, Jamie Benoit, Tetsuya Yamagata

Human Gene Therapy · 01.03.2026 · 37 (5-6) · 210-222

DOI: 10.1177/10430342251401873 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Gene Therapy, online erschienen am 08.02.2026. Verfasst von Yuanbo Qin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Modalis Therapeutics, Inc., Waltham, Massachusetts, USA. Hauptthemen laut MEDLINE: Gene Editing, Muscular Dystrophies, Genetic Therapy, Laminin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epigenome editing technology holds great promise for treating diverse genetic disorders. In this study, we demonstrate epigenetic activation of the LAMA1 gene for the treatment of LAMA2 -CMD, a severe congenital muscle dystrophy (CMD) caused by biallelic mutations in the LAMA2 gene. LAMA1 is a sister homolog that is known to compensate for the function of LAMA2 . However, supplementing LAMA1 or LAMA2 gene via viral platform is not feasible due to the large size of their coding sequences. Through a single administration of our adeno-associated virus (AAV) vector encoding all the necessary elements for epigenetic activation, we observed significant LAMA1 gene upregulation and phenotype improvements in mouse disease models. The muscle-tropic AAV capsid exhibited desired vector biodistribution and promising pharmacodynamics with good safety profiles in 2-year-old juvenile nonhuman primates (NHPs). Moreover, administration to 8-month-old infant NHPs demonstrated superior pharmacodynamics compared with 2-year-old juveniles, even at half the dose. Our approach holds broad applicability for a range of loss-of-function genetic disorders and could offer a therapeutic breakthrough where active epigenome offers clinical benefit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gene EditingMuscular DystrophiesGenetic TherapyLamininEpigenesis, GeneticEpigenomeAnimalsDependovirusMiceHumansGenetic VectorsDisease Models, AnimalEpigenome Editing

Stichwörter der Autor:innen

AAVCRISPRLAMA1LAMA2-CMDMDC1Aepigenetic editinggene therapy

Substanzen

Lamininlaminin Alaminin alpha 2

Autor:innen und Institutionen

  • Modalis Therapeutics, Inc., Waltham, Massachusetts, USA.

Zitieren

APA

Qin, Y., Akbulut, T., Mandraju, R., Connolly, K., Bechill, J., Assadian, F., Foster, C., Shottek, A., Levy, S., Benoit, J., & Yamagata, T. (2026). Efficient LAMA1 Gene Activation by Epigenome Editing as a Therapeutic Approach for LAMA2-CMD. Human Gene Therapy, 37(5-6), 210-222. https://doi.org/10.1177/10430342251401873

Vancouver

Qin Y, Akbulut T, Mandraju R, Connolly K, Bechill J, Assadian F, et al. Efficient LAMA1 Gene Activation by Epigenome Editing as a Therapeutic Approach for LAMA2-CMD. Human Gene Therapy. 2026;37(5-6):210-222. doi:10.1177/10430342251401873

BibTeX
@article{Qin2026,
  author = {Qin, Yuanbo and Akbulut, Talha and Mandraju, Rajakumar and Connolly, Keith and Bechill, John and Assadian, Farzaneh and Foster, Claudia and Shottek, Alison and Levy, Seth and Benoit, Jamie and Yamagata, Tetsuya},
  title = {Efficient LAMA1 Gene Activation by Epigenome Editing as a Therapeutic Approach for LAMA2-CMD},
  journal = {Human Gene Therapy},
  year = {2026},
  volume = {37},
  number = {5-6},
  pages = {210--222},
  doi = {10.1177/10430342251401873}
}
Kostenlos starten →